Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's TRiM TM technology, at The Liver Meeting
View HTML
Toggle Summary Arrowhead to Present at Chardan Gene Therapy Conference
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Chardan Gene Therapy Conference - New York , October 10, 2017 October 10 , 10:45 a.m.
View HTML
Toggle Summary Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
- Results May Guide New Clinical Approaches, Science Translational Medicine Study Shows - PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic hepatitis B
View HTML
Toggle Summary Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), is hosting an investor & analyst R&D day in New York today to introduce its proprietary Targeted RNAi Molecule (TRiM TM ) platform and review its pipeline of RNAi therapeutic candidates.
View HTML
Toggle Summary Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming event: 2017 Cantor Fitzgerald Global Healthcare Conference - New York , September 25-27, 2017 September 25 , 9:10 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development Day to discuss its pipeline of RNAi-based therapies on September 14 in New York City . The R&D Day will feature presentations by key opinion leaders (KOLs)
View HTML
Toggle Summary Arrowhead Reports Fiscal 2017 Third Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Thursday, August 3, 2017 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 third quarter ended June 30, 2017 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 5, 2017 , eleven new employees were awarded "inducement" grants of options under Rule 5635(c)(4) of the NASDAQ Marketplace
View HTML
Toggle Summary Arrowhead Reports Fiscal 2017 Second Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017 . The company is hosting a conference call at 4:30 p.m.
View HTML